Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.

Date publication

décembre 2024

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LANCON Allan , Dr COLLONGE-RAME Marie-Agnès , Dr NAMBOT Sophie

Tous les auteurs :
Poumeaud F, Valentin T, Fares N, Segier B, Watson S, Verret B, Tlemsani C, Penel N, Lejeune S, Firmin N, Sabouret A, Thery JC, Bonvalot S, Cottereau E, Cauchin E, Lancon A, Nambot S, Zattara H, Coudert M, Fourme E, Nogues C, Tougeron D, Prieur F, Collonge-Rame MA, Denis C, Laurent-Puig P, Chieze-Valero S, Dreyfus H, Jaffrelot M, Vande Perre P, Rochaix P, Gomez-Mascard A, Rochefort P, Campoy S, Chibon F, Lasset C, Selves J, Guimbaud R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39742560

Résumé

Sarcomas do not belong to the Lynch Syndrome (LS)-tumour spectrum. A growing body literature has reported sarcomas in patients with LS. Clinical and tumour characteristics of these patients remain unknown.

Mots clés

Deficient mismatch repair, Immune checkpoint inhibitors, Lynch Syndrome, MSH2, Microsatellite instability, Pleomorphic rhabdomyosarcomas

Référence

Eur J Cancer. 2024 12 21;216:115196